Skip to main content
MANE
NYSE Life Sciences

Director and 10% Owner Suvretta Capital Management Makes $10.5M Open Market Purchase

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Positive
Importance info
8
Price
$37.03
Mkt Cap
$1.299B
52W Low
$32
52W High
$40.11
Market data snapshot near publication time

summarizeSummary

Suvretta Capital Management, a Director and 10% owner of Veradermics, Inc., executed substantial open market purchases totaling over $10.5 million, signaling strong conviction following the company's recent IPO.


check_boxKey Events

  • Significant Insider Purchase

    Suvretta Capital Management, acting as a Director and 10% owner, acquired 282,674 shares of Veradermics common stock through open market transactions.

  • Substantial Investment

    The total value of these purchases amounted to approximately $10.5 million, representing a notable investment in the company.

  • Post-IPO Accumulation

    These transactions occurred between February 4th and February 6th, immediately following Veradermics' Initial Public Offering and align with a broader trend of insider accumulation.

  • Cluster Buying

    This purchase contributes to a pattern of significant insider buying observed since the IPO, with other directors and 10% owners also making substantial investments.


auto_awesomeAnalysis

This Form 4 filing reveals a significant open market purchase by Suvretta Capital Management, which holds roles as both a Director (by deputization) and a 10% owner of Veradermics, Inc. The acquisition of over $10.5 million in common stock, occurring shortly after the company's Initial Public Offering, demonstrates strong confidence from a key institutional investor with board representation. This transaction is part of a broader trend of accumulation by multiple insiders, including other directors and 10% owners, as evidenced by recent Form 4 filings. Such a cluster of insider buying post-IPO can be interpreted as a positive signal, suggesting that those closest to the company believe the shares are undervalued or that future prospects are strong. Investors should note the collective conviction shown by these substantial investments.

At the time of this filing, MANE was trading at $37.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $32.00 to $40.11. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MANE - Latest Insights

MANE
Apr 27, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
9
MANE
Mar 30, 2026, 8:44 AM EDT
Filing Type: 8-K
Importance Score:
9
MANE
Mar 30, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
MANE
Feb 12, 2026, 6:11 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
MANE
Feb 11, 2026, 5:22 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
MANE
Feb 11, 2026, 4:29 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
MANE
Feb 09, 2026, 6:28 PM EST
Filing Type: 4
Importance Score:
8
MANE
Feb 05, 2026, 7:04 PM EST
Filing Type: 4
Importance Score:
9
MANE
Feb 05, 2026, 7:04 PM EST
Filing Type: 4
Importance Score:
9
MANE
Feb 05, 2026, 7:03 PM EST
Filing Type: 4
Importance Score:
8